Ad-IFNα2α1

Ad-IFNα2α1 is a replication-deficient adenoviral gene therapy vector that encodes a chimeric human "hybrid" interferon-alpha protein. This hybrid protein consists of the N-terminus of human interferon-alpha 2 (IFN-α2) joined to the C-terminus of human interferon-alpha 1 (IFN-α1). Unlike standard human IFN-α2b, which is species-restricted, this "universal" interferon (also known as IFN A/D) exhibits biological activity in cells from a variety of mammalian species, including both humans and mice. Developed by Canji (a subsidiary of Schering-Plough), Ad-IFNα2α1 was primarily used in preclinical research for the treatment of superficial bladder cancer (non-muscle invasive bladder cancer). When formulated with the excipient Syn3, it facilitates high and sustained local expression of the therapeutic protein in the bladder urothelium, demonstrating the ability to overcome resistance to recombinant interferon protein therapy through direct antitumor activity and significant bystander effects.

Other names

universal interferonIFN A/DrAd-IFNα2α1Ad-IFNα2/α1